Is Radiopharm Theranostics Limited (RADX) a good stock to buy?

Olyth's institutional analysis of RADX reveals an Altman Z-Score of undefined and a Piotroski F-Score of undefined/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if RADX fits their risk profile.

What is the current P/E ratio for RADX?

As of the latest trading session, Radiopharm Theranostics Limited (RADX) has a trailing P/E ratio of -1.12.

Who is the CEO of Radiopharm Theranostics Limited?

The current Chief Executive Officer of Radiopharm Theranostics Limited is Riccardo Canevari.

What was RADX's revenue for the last 5 years?

According to its latest income statements, Radiopharm Theranostics Limited reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022) respectively.

Does RADX pay a dividend?

Radiopharm Theranostics Limited does not currently pay a dividend to its shareholders.

How much debt and cash flow does RADX have?

In its latest reporting period, Radiopharm Theranostics Limited generated $-0.04B in Free Cash Flow against a total debt load of $N/A.

What is the Price-to-Book (P/B) ratio of Radiopharm Theranostics Limited?

The Price-to-Book (P/B) ratio for Radiopharm Theranostics Limited (RADX) is currently 0.96.

What is the Price-to-Sales (P/S) ratio of RADX?

Based on trailing twelve-month data, Radiopharm Theranostics Limited (RADX) trades at a Price-to-Sales (P/S) ratio of 2.19.

What is Radiopharm Theranostics Limited's Return on Equity (ROE)?

Radiopharm Theranostics Limited (RADX) has a Return on Equity (ROE) of -105.17%, representing its profitability relative to shareholder equity.

RADX

Radiopharm Theranostics Limited · Healthcare

4.35

1.58%(-0.07)

4.33

0.46%(-0.02)

After Hours

Last Updated: — ET

52W L: $3.6252W H: $16.25

$4.32

CHG-0.48 (-10.00%)

H$6.31

L$3.79

VOL1.3M

RADX (1h)

Company Profile

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2024-12-05

Beta

0.84

Websitewww.radiopharmtheranostics.com↗

RADX

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial

Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial

Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study

Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results